Craniofacial metastases: a 20-year survey

In this study we analysed the long-term prognosis of 52 patients with distant metastases to the craniofacial area. All patients were treated in our department between 1989 and 2009. Possible predictive factors for the overall survival prognosis like age, gender, histopathological type of the metasta...

Full description

Saved in:
Bibliographic Details
Main Authors: Thiele, Oliver C. (Author) , Freier, Kolja (Author) , Bacon, Claire (Author) , Flechtenmacher, Christa (Author) , Scherfler, Sebastian (Author) , Seeberger, Robin (Author)
Format: Article (Journal)
Language:English
Published: 2011
In: Journal of cranio-maxillofacial surgery
Year: 2011, Volume: 39, Issue: 2, Pages: 135-137
ISSN:1878-4119
DOI:10.1016/j.jcms.2010.10.009
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jcms.2010.10.009
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1010518210001939
Get full text
Author Notes:Oliver C. Thiele, Kolja Freier, Claire Bacon, Christa Flechtenmacher, Sebastian Scherfler, Robin Seeberger
Description
Summary:In this study we analysed the long-term prognosis of 52 patients with distant metastases to the craniofacial area. All patients were treated in our department between 1989 and 2009. Possible predictive factors for the overall survival prognosis like age, gender, histopathological type of the metastasis, location and tissue structure of the area in the head and neck region, time between primary tumour and metastasis and the therapy were evaluated. 62% of the patients with distant metastases in the craniofacial area were male (32/52), the average age was 63 years. Adenocarcinoma was the most common histological type (20/52) and lung (12/52), malignant melanoma of the skin (9/52) and breast (8/52) the most common primary tumour site. In 35% of all patients, the primary tumour was not known at the time of the diagnosis of the craniofacial metastasis, this number reduced to 17% without the patients with a CUP syndrome. Patients survived an average of 14.4 months after manifestation of the metastases and 43.4 months after the manifestation of the primary tumour.
Item Description:Gesehen am 02.11.2022
Erstmals online zugänglich am 1. November 2010
Physical Description:Online Resource
ISSN:1878-4119
DOI:10.1016/j.jcms.2010.10.009